HIV Prevention & Access
Development and distribution of HIV prevention medications including long-acting injectables, raising questions about equitable global access and healthcare equity.
3 events tracked
Latest in HIV Prevention & Access· Oct 16
Gene therapies for sickle cell disease have demonstrated clinical efficacy, opening a new treatment category with potential implications for patient outcomes. However, significant access barriers—including high costs, limited manufacturing capacity, geographic distribution constraints, and insurance coverage gaps—threaten to prevent many patients from benefiting from these advances despite their clinical promise. These obstacles create a disconnect between therapeutic capability and real-world availability, affecting both the commercial viability of treatments for developers and healthcare systems' ability to deliver care at scale.
- Single source6 days ago
Sickle cell treatments show promise despite barriers to patient access
Sickle cell gene therapies show clinical promise but face barriers to patient access and adoption.
CNBC
- Single source21 days ago
Twice-yearly HIV injection shows promise amid access concerns
HIV prevention drug advances as breakthrough, raising questions about equitable global access and distribution.
Al Jazeera
- Single source22 days ago
Experimental HIV preventive injection raises concerns over global availability
New HIV vaccine candidate shows promise; access and distribution questions emerge.
Al Jazeera